Updated on 8 February 2013
The co-promotion agreement commences in April 2013
Singapore: Biosensors International, a developer, manufacturer and marketer of innovative medical devices, is collaborating with Japanese company Terumo to promote the Nobori drug-eluting stent (DES) system at specific specialist cardiology centers in Japan.
Nobori incorporates two elements of Biosensors-developed technology: Biolimus A9 (BA9), an anti-restenotic drug developed specifically for use with stents; and a unique abluminal biodegradable polymer coating. Following an agreement with Terumo to manufacture, market and sell DES systems incorporating this technology in Japan, Terumo introduced Nobori there in May 2011.
Since this time, the DES market in Japan has become increasingly competitive. This new agreement will allow two sales forces (Terumo and Biosensors Japan) to jointly promote Nobori, highlighting its outstanding long-term efficacy and safety.
"We have established a strong partnership with Terumo over many years, and are delighted by this latest agreement, which further enhances our long-term strategic relationship," commented Mr Jeffrey B. Jump, president of Biosensors' Cardiovascular Business Unit. "Our two companies will continue to work closely together to strengthen our respective technologies and provide continued patient benefit in Japan."
The co-promotion agreement commences in April 2013, for an initial period of three years.